PANITUMUMAB IS A RECOMBINANT, FULLY HUMAN IgG2 MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO HUMAN EGFR1*

Panitumumab, a fully human IgG2 monoclonal antibody, binding to EGFR expressed on the cell surface.1

EGFR is a transmembrane glycoprotein that promotes cell growth in normal epithelial cells and is expressed on the surface of various tumour cells.

KRAS and NRAS genes encode small, GTP-binding proteins involved in signal transduction. A variety of stimuli, including that from the EGFR, activate KRAS and NRAS, which in turn stimulate other intracellular proteins to promote cell proliferation, cell survival, and angiogenesis.1

EGFR ligands bind to the receptor and activate EGFR signalling by inducing receptor autophosphorylation.1

  • A variety of stimuli, including that from EGFR, activate KRAS and NRAS, highly related members of the RAS oncogene family that encode small, GTP-binding proteins involved in signal transduction.
  • This activation stimulates other intracellular proteins to promote cell proliferation, cell survival, and angiogenesis.
Panitumumab binds to the ligand-binding domain of EGFR and competitively inhibits receptor autophosphorylation induced by all known EGFR ligands

Panitumumab binds to the ligand-binding domain of EGFR and competitively inhibits receptor autophosphorylation induced by all known EGFR ligands.1

  • Binding of panitumumab to EGFR results in:1
    • EGFR receptor internalization
    • Cell growth inhibition
    • Apoptosis induction
    • Decrease in IL-8 and VEGF

Adapted from Vectibix Product Monograph.1

mid-bg

* Clinical significance has not been established.
EGFR, epidermal growth factor receptor; GTP, guanosine triphosphate; IL-8, interleukin 8; KRAS, Kirsten rat sarcoma viral oncogene homolog; NRAS, Neuroblastoma RAS viral oncogene homolog;
RAS, rat sarcoma viral oncogene homolog; VEGF, vascular endothelial growth factor.